USFDA issues warning letter to Glenmark Pharma for lapses at Goa plant ...Middle East

The US health regulator has pulled up drug maker Glenmark Pharmaceuticals for manufacturing lapses, including failure to establish required laboratory control mechanisms, at its Goa-based manufacturing plant. In a warning letter addressed to Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha, the US Food and Drug Administration (USFDA) pointed out various lapses at the company's Bardez-based facility in Goa, which produces drug formulations. The US Health regulator noted that the "warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals". It further said: "Because your methods, facilities, or c

Hence then, the article about usfda issues warning letter to glenmark pharma for lapses at goa plant was published today ( Sunday 11/12/2022 - 11:04 AM ) and is available on Business Standard ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( USFDA issues warning letter to Glenmark Pharma for lapses at Goa plant )

Also on site :

• Hikvision earns ISO/IEC 29147 and ISO/IEC 30111 certification for vulnerability management
• Körber to acquire majority stake in Stellium to expand supply chain consulting capabilities
• iQIYI Reaches New Heights: 880 Invention Patents Filed in 2025, Over Half Driven by AI Innovation, Further Building Up Its AIGC Leadership